Bionaut Labs Overview
Bionaut Labs is a biotechnology start-up focused on treating central nervous system disorders (CNS) with its Bionaut precision medicine treatment modality. Bionaut uses remote-controlled microscale robots to deliver biologics, nucleic acids, or small molecule therapies locally to targeted CNS disease areas. Through precision localized brain targeting, Bionaut therapeutics could offer better efficacy and safety that cannot be achieved by other traditional treatment modalities. Two of the company's earliest indications are for gliomas and Huntington's disease. The Bionaut therapeutic-containing drug targets a disease similarly to how a traditional modality targets a disease. Bionauts are custom-engineered therapeutic micro-robots that target payloads to specific locations in the body. Bionauts can be constructed in different versions with custom geometries and surface characteristics. Smaller than a millimeter, they contain moving parts controlled remotely by a compact magnetic controller, allowing them to move.
Cumulative Funding Raised Over Time ($)
$6.0MFeb 2024
$26.0MMar 2021
$69.2MNov 2022
Latest News
growth-positive
Exclusive: Bionaut Labs raises an extension round in preparation for micro-robot clinical trials
Bionaut Labs, a medical micro-robots startup, is developing micro-robots that can deliver drugs to hard-to-reach areas in the human brain. The company has successfully tested its technology on animals and is preparing for human clinical trials. Bionaut has raised an extension round of funding from Mayo Clinic, Khosla Ventures, Upfront Ventures, OurCrowd, and reportedly, Gates Ventures. To date, the company has raised over $70 million. The micro-robots, about the size of a grain of rice, are controlled through magnetism and can deliver drugs more accurately than current methods.
Investment
growth-positive
Micro-robots could deliver drugs to brain and organs - ISRAEL21c
Bionaut Labs, a company co-founded by successful Israeli tech entrepreneurs Michael Shpigelmacher, Aviad Maizels and Alex Shpunt, is developing micro-robots called Bionauts for medical purposes. The robots can be inserted into the cerebrospinal fluid and guided to organs that are difficult to reach. The company aims to use these robots to fight serious illnesses, starting with brain diseases. The company has raised over $63 million and is a year away from clinical trials. If successful, the US Food and Drug Administration might authorize the use of Bionauts as soon as 2027 or 2028.
Investment
growth-positive
Drug delivery robots co Bionaut Labs raises $43m
Bionaut Labs, a drug delivery robots company, has completed a $43.2 million Series B financing round led by Khosla Ventures. The funds raised will be used to advance clinical development of the companys lead programs against malignant glioma brain tumors and Dandy-Walker Syndrome. The total financing raised by the company to date is $63.2 million. Bionaut Labs aims to develop microscale drug delivery robots that can navigate deep into the human body to deliver drugs locally, avoiding side effects and toxicity. The companys co-founders have a background in robotics and previously co-founded PrimeSense, which was acquired by Apple for $400 million.
Investment
growth-positive
The Fantastic Voyage coming soon to an OR near you - Sponsored Content The Times of Israel
Israeli startup Bionaut Labs has developed a miniature micro-robot capsule that can deliver targeted chemotherapy directly to the innermost regions of the brain. The capsule is controlled externally using a magnetic device and can be programmed to navigate through the brain tissue to reach the tumor. Bionaut Labs has received interest from pharmaceutical companies for potential partnerships. The company expects to begin clinical trials in about one year and has already received FDA Orphan Drug designation for the treatment of malignant gliomas. The micro-robot has the potential to bypass the blood-brain barrier and deliver medication without damaging surrounding tissue.
Partners
growth-positive
Are Bionauts™ a Vessel to the Final Frontier of CNS Diseases? BioSpace
Bionaut Labs, a company specializing in using remote-controlled microscale robots to deliver therapies to the brain, has emerged from stealth mode with a $20 million Series A funding round. The companys Bionauts™ have the potential to revolutionize the treatment of brain diseases by providing targeted delivery of biologics, nucleic acids, or small molecule therapies to precise areas of the brain. The funding round was led by Khosla Ventures, with participation from Upfront Ventures, Revolution, BOLD Capital, and Compound. Bionaut Labs plans to conduct further studies and aims to reach the clinic in 2023. The companys technology has the potential to improve the efficacy of gene therapies and other treatments by providing anatomical and biochemical precision in drug delivery.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $69.2M |
| Last funding | $6M |
| Stage | B |
| Rounds | 3 |
| Investors | 15 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | bionautlabs.com |
| Careers | Careers page |
Locations
Arieh Shenkar Street 1, Herzliya, Israel
3767 Overland Ave, Los Angeles, CA, USA
Photos & Videos
2 item(s)
Bionaut Labs Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Machinery & RoboticsTags (14)
diagnosticsbiotechnologyrare-diseasesdrug-deliverybrain-disorderprecision-medicineparkinsontherapeuticsneurologyminimally-invasivecns-disorderstargeted-therapyroboticssurgeryBionaut Labs Financials
$69.2M
Total funding
Undisclosed
Capital raised
$6M
Last funding
B
Funding stage
3
Total rounds
15
Investors
Cumulative Funding Raised Over Time ($)
$6.0MFeb 2024
$26.0MMar 2021
$69.2MNov 2022
Private Equity Funding
B Round
Feb 2024
$6M
OurCrowd, Upfront Ventures, Mayo Clinic Platform, Khosla Ventures
B Round
Nov 2022
$43.2M
Khosla Ventures (Lead)
,
Dolby Ventures, Compound, OurCrowd, GISEV, Bold Capital Partners, Revolution, Tintah Grace, What if Ventures, Sixty Degree Capital, PSPRS, Upfront Ventures, Deep Insight, Gaingels
A Round
Mar 2021
$20M
Khosla Ventures (Lead)
,
Upfront Ventures, Bold Capital Partners, Revolution, Compound
Bionaut Labs Lifecycle
Cumulative Funding Raised Over Time
$6.0MFeb 2024
$26.0MMar 2021
$69.2MNov 2022
All Events
B Round
Feb 2024
$6M
OurCrowd, Upfront Ventures, Mayo Clinic Platform, Khosla Ventures
B Round
Nov 2022
$43.2M
Khosla Ventures (Lead)
,
Dolby Ventures, Compound, OurCrowd, GISEV, Bold Capital Partners, Revolution, Tintah Grace, What if Ventures, Sixty Degree Capital, PSPRS, Upfront Ventures, Deep Insight, Gaingels
A Round
Mar 2021
$20M
Khosla Ventures (Lead)
,
Upfront Ventures, Bold Capital Partners, Revolution, Compound
Bionaut Labs News
7 articles
growth-positive
Exclusive: Bionaut Labs raises an extension round in preparation for micro-robot clinical trials
Bionaut Labs, a medical micro-robots startup, is developing micro-robots that can deliver drugs to hard-to-reach areas in the human brain. The company has successfully tested its technology on animals and is preparing for human clinical trials. Bionaut has raised an extension round of funding from Mayo Clinic, Khosla Ventures, Upfront Ventures, OurCrowd, and reportedly, Gates Ventures. To date, the company has raised over $70 million. The micro-robots, about the size of a grain of rice, are controlled through magnetism and can deliver drugs more accurately than current methods.
Investment
growth-positive
Micro-robots could deliver drugs to brain and organs - ISRAEL21c
Bionaut Labs, a company co-founded by successful Israeli tech entrepreneurs Michael Shpigelmacher, Aviad Maizels and Alex Shpunt, is developing micro-robots called Bionauts for medical purposes. The robots can be inserted into the cerebrospinal fluid and guided to organs that are difficult to reach. The company aims to use these robots to fight serious illnesses, starting with brain diseases. The company has raised over $63 million and is a year away from clinical trials. If successful, the US Food and Drug Administration might authorize the use of Bionauts as soon as 2027 or 2028.
Investment
growth-positive
Drug delivery robots co Bionaut Labs raises $43m
Bionaut Labs, a drug delivery robots company, has completed a $43.2 million Series B financing round led by Khosla Ventures. The funds raised will be used to advance clinical development of the companys lead programs against malignant glioma brain tumors and Dandy-Walker Syndrome. The total financing raised by the company to date is $63.2 million. Bionaut Labs aims to develop microscale drug delivery robots that can navigate deep into the human body to deliver drugs locally, avoiding side effects and toxicity. The companys co-founders have a background in robotics and previously co-founded PrimeSense, which was acquired by Apple for $400 million.
Investment
growth-positive
The Fantastic Voyage coming soon to an OR near you - Sponsored Content The Times of Israel
Israeli startup Bionaut Labs has developed a miniature micro-robot capsule that can deliver targeted chemotherapy directly to the innermost regions of the brain. The capsule is controlled externally using a magnetic device and can be programmed to navigate through the brain tissue to reach the tumor. Bionaut Labs has received interest from pharmaceutical companies for potential partnerships. The company expects to begin clinical trials in about one year and has already received FDA Orphan Drug designation for the treatment of malignant gliomas. The micro-robot has the potential to bypass the blood-brain barrier and deliver medication without damaging surrounding tissue.
Partners
growth-positive
Are Bionauts™ a Vessel to the Final Frontier of CNS Diseases? BioSpace
Bionaut Labs, a company specializing in using remote-controlled microscale robots to deliver therapies to the brain, has emerged from stealth mode with a $20 million Series A funding round. The companys Bionauts™ have the potential to revolutionize the treatment of brain diseases by providing targeted delivery of biologics, nucleic acids, or small molecule therapies to precise areas of the brain. The funding round was led by Khosla Ventures, with participation from Upfront Ventures, Revolution, BOLD Capital, and Compound. Bionaut Labs plans to conduct further studies and aims to reach the clinic in 2023. The companys technology has the potential to improve the efficacy of gene therapies and other treatments by providing anatomical and biochemical precision in drug delivery.
Investment
growth-positive
Khosla-backed Bionaut Labs Exits Stealth Mode With $20M
Bionaut Labs, a Los Angeles-based company, has launched its microscale robots for precision treatment of brain disorders. The company has received $20 million in financing, led by Khosla Ventures. The microscale robots, about one millimeter in size, are injected into the spine and directed into the brain using a magnetic remote control. The company aims to demonstrate the efficacy and safety of its robots through large animal testing and eventually human clinical trials. Bionaut Labs is focused on developing treatments for brain stem glioma and Huntingtons disease, with plans to enter the clinic in 2023. The precision medicine market is expected to reach $105.6 billion by 2026. Bionaut Labs is also exploring opportunities in ophthalmology and targeted drug delivery for other diseases.
Investment
growth-positive
Khosla joins bet on unconventional startup looking to send drug delivering robots into the brain
The article discusses Michael Shpigelmachers project to build the real-life equivalent of technology from the film Fantastic Voyage. He funded the project himself and also received some seed cash from friends and family. The project is considered risky by investors, but Shpigelmacher is determined to make it a reality.
Bionaut Labs Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 42 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.
Bionaut Labs Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 515385334 |
| Crunchbase | bionaut-labs |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-05-28T00:00:00.000Z |
| Created | 2016-05-20T00:00:00.000Z |